Methods for the treatment of depression
AssigneeJanssen Pharmaceutica NV
InventorsLodewijk Ivo Caers, Jaskaran Singh, Peter Nicholas Zannikos, Wayne C. Drevets, Ella Daly, Carla Marie Canuso, Margaret Fedgchin, Frank Wiegand
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).
Claims30
A method of treating major depressive disorder in a human patient in need thereof, comprising:
- intranasally administering (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction dosage to the patient in an amount in the range of from about 56 mg to about 84 mg in an induction phase, wherein the induction phase comprises a treatment period of about four weeks, and the induction dosage is administered at a frequency of twice per week during the induction phase.
A method of treating depression in a human patient in need thereof, the method having an induction phase and a subsequent maintenance phase, comprising:
- intranasally administering (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in an induction dosage to the patient in an amount in the range of from about 28 mg to about 84 mg in the induction phase, wherein the induction phase comprises a treatment period of about four weeks, and the induction dosage is administered at a frequency of twice per week during the induction phase;
- and
- intranasally administering (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone in a maintenance dosage in an amount in the range of from about 56 mg to about 84 mg in the maintenance phase, wherein the maintenance dosage is administered at a frequency of once per week or once every two weeks.
Dependencies are inferred from the claim text.